Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer

InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2

NCT05835739 ·Status: RECRUITING

Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype

NCT06813456 ·Status: RECRUITING

Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis

NCT05730010 ·Status: COMPLETED

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

NCT05770531 ·Status: RECRUITING ·Phase: PHASE2

Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy

NCT05649475 ·Status: UNKNOWN

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

NCT07025785 ·Status: RECRUITING ·Phase: NA

Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

NCT03688035 ·Status: UNKNOWN

Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer

NCT07132502 ·Status: NOT_YET_RECRUITING

Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients

NCT03881384 ·Status: UNKNOWN

Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer

NCT01048918 ·Status: COMPLETED

Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics

NCT03511859 ·Status: UNKNOWN

PIK3CA Mutational Status Assessment

NCT06706570 ·Status: RECRUITING

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

NCT05814224 ·Status: UNKNOWN ·Phase: NA

Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107

NCT07292571 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study

NCT04579484 ·Status: UNKNOWN

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

NCT06762977 ·Status: RECRUITING

Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer

NCT03260192 ·Status: RECRUITING

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

NCT06663787 ·Status: ACTIVE_NOT_RECRUITING

Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer

NCT00898014 ·Status: COMPLETED

Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer

NCT03161834 ·Status: WITHDRAWN

Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR

NCT03947736 ·Status: UNKNOWN

A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients

NCT06833853 ·Status: RECRUITING

Study of Metabolites Markers in Adjuvant Breast Cancer

NCT03367208 ·Status: COMPLETED

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

NCT06551116 ·Status: RECRUITING

(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer

NCT02627703 ·Status: UNKNOWN